Therefore, we speculate that targeting HCC cells by inhibiting the Ras/Raf/ERK signaling pathway, rather than targeting endothelial cells by inhibiting angiogenesis, is probably the primary contribution to the anti-tumor efficacy of sorafenib. The gene discussed is RAF1; the disease is hepatocellular carcinoma.